Pfizer (NYSE: PFE) announced that the 10 milligram dose of tofacitinib, its experimental JAK inhibitor for rheumatoid arthritis (RA), met all primary endpoints in a phase 3 study. Patients taking the drug showed statistically significant changes in the signs and symptoms of the disease, as well as a slowing of structural damage of the joints, when compared to patients on placebo. The smaller dose, 5 milligrams, improved symptoms but did not significantly reduce structural damage. The company plans to release additional data at an upcoming medical meeting.
By posting a comment, you agree to our terms and conditions.